Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142800 · ClinicalTrials.gov registry record
Screening For BCRL In Targeted Therapy For Breast Cancer
A clinical trial of Lymphedema and Breast Cancer Metastatic, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 166
- Enrollment target
- 1
- Study location
NCT05142800 is a study of Lymphedema and Breast Cancer Metastatic that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 166 participants, below the 9,295-participant average among 34 other Lymphedema trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05142800, a study of Lymphedema and Breast Cancer Metastatic, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer. A Perometer and Sozo devise will be used to measure volume changes
Conditions Studied
Interventions
- DEVICE Perometer
- DEVICE SOZO device
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2026-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05142800
The ClinicalTrials.gov registry entry for NCT05142800 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,295-participant average among 34 other Lymphedema trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which Perometer is the first listed.
NCT05142800 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05142800 about?
NCT05142800 is a clinical study titled "Screening For BCRL In Targeted Therapy For Breast Cancer". This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer. A Perometer and Sozo devise will be used to measure volume changes
What is the current status of trial NCT05142800?
This trial is currently active not recruiting. The enrollment target is 166 participants. The study started on 2018-12-13. Estimated completion is 2026-09-30.
What conditions does trial NCT05142800 study?
This clinical trial studies the following conditions: Lymphedema, Breast Cancer Metastatic, Edema, Lymphedema Arm, Lymphedema of Upper Arm.
What interventions are being tested in trial NCT05142800?
The interventions under investigation include: Perometer (DEVICE), SOZO device (DEVICE).
Who is sponsoring clinical trial NCT05142800?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05142800 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphedema Surveillance Study
RECRUITING
-
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
RECRUITING · Early Phase 1
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.